These top level issues are discussed in our White Papers, leveraging our industry expertise to help customers answer the most challenging preclinical research questions.
The biggest challenge in modeling human diabetes in animal models is a lack of translatable platforms fully capturing all aspects of this progressive condition including polygenic disease, pre-diabetic state, and complications. New translational platforms are required that model multiple aspects of human disease, and can be used to develop agents that control more than one diabetes risk factor. Read our White Paper to learn about the development of highly translatable rodent and NHP models, more closely mirroring human disease development for more predictive preclinical study.
With the continued rise of immunotherapeutics, more preclinical research is moving towards using immunocompentent models, which are required to assess immunomodulatory agents. Choosing the correct model from the variety available can be difficult, but is needed to help to efficiently progress novel agents. Download our White Paper to learn which human specific and mouse analogue models are available, and how to select the best model for any given immuno-oncology study.
Oncology drug development has an overly high attrition rate for novel agents in late-phase clinical trials, which needs to be improved to enhance the efficiency and cost-effectiveness of developing new therapies. Precision profiling using Patient-Derived Xenografts (PDX), the most predictive preclinical models available, allows the identification of molecular biomarkers and genetic signatures of response for patient stratification to improve response and reduce attrition rates. Let CrownBio’s Precision Profiling White Paper help you understand who will benefit from your treatment before you enter the clinic.